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A putative functional role for oligodendrocytes
in mood regulation
N Edgar and E Sibille
Altered glial structure and function is implicated in several major mental illnesses and increasing evidence speciﬁcally links
changes in oligodendrocytes with disrupted mood regulation. Low density and reduced expression of oligodendrocyte-speciﬁc
gene transcripts in postmortem human subjects points toward decreased oligodendrocyte function in most of the major mental
illnesses. Similar features are observed in rodent models of stress-induced depressive-like phenotypes, such as the
unpredictablechronicmildstressandchroniccorticosterone exposure, suggestinganeffectdownstreamfromstress.However,
whether oligodendrocyte changes are a causal component of psychiatric phenotypes is not known. Traditional views that
identify oligodendrocytes solely as nonfunctional support cells are being challenged, and recent studies suggest a more
dynamic role for oligodendrocytes in neuronal functioning than previously considered, with the region adjacent to the node of
Ranvier (i.e., paranode) considered a critical region of glial–neuronal interaction. Here, we brieﬂy review the current knowledge
regardingoligodendrocytedisruptionsinpsychiatricdisordersandrelatedanimalmodels,withafocusonmajordepression.We
then highlight several rodent studies, which suggest that alterations in oligodendrocyte structure and function can produce
behavioral changes that are informative of mood regulatory mechanisms. Together, these studies suggest a model, whereby
impaired oligodendrocyte and possibly paranode structure and function can impact neural circuitry, leading to downstream
effects related to emotionality in rodents, and potentially to mood regulation in human psychiatric disorders.
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Oligodendrocytes
In the adult central nervous system (CNS), glial cells refer to a
set of non-neuronal cells that provide support to neurons, and
that include astrocytes, oligodendrocytes, ependymal cells
and microglia. Glial abnormalities are postulated to be
involved in the pathophysiology of a variety of neuropsychia-
tric illnesses.
1–4 Oligodendrocytes, the main myelin forming
cells of the central nervous system, have recently begun to
garner more attention owing to reports of widespread
disruption of oligodendrocytes across psychiatric disorders.
4
In addition, recent ﬁndings suggest that myelin constitution
can inﬂuence neuronal properties in ways not previously
considered, and may be a source of essential trophic and
metabolic support for maintaining axonal integrity,
5 thereby
opening new research avenues into the functional role of
oligodendrocytes in disease.
Overview of oligodendrocyte structure and function. Oligo-
dendrocytes have a small round cell body and about four to six
branching processes, which can myelinate up to 60 axons
depending upon the diameter.
6 Total oligodendrocyte numbers
vary across brain regions
7 and the local density depends on
axonal density.
8 Myelin consists of lipids (70%) and a variety of
proteins (30%), including myelin basic protein (MBP), proteolipid
protein (PLP) and 20,30-cyclic nucleotide-30-phosphodiesterase
(CNP), which together represent the major protein components
of myelin.
9,10 When ensheathing axons, the opposing lipid
bilayers are fused and then form compacted concentric layers
(lamellae) around the bare axon (typically 10–100 lamellae).
Functionally, mature oligodendrocytes provide critical insulation
to facilitate axonal conduction by increasing the resistance and
lowering the capacitance of the axonal membrane, which allows
faster conduction speed in myelinated axons compared to
unmyelinated axons of the same diameter. Oligodendrocytes
also have a role in regulating the development and periodicity of
nodes of Ranvier, spaces of bare axon, which contain ion
channels critical for action potential propagation along the axon.
At the ends of the internodal regions, the myelin lamellae form a
tight association (septate-like junction) with the axon, termed the
paranode region, with the axonal proteins Contactin and Caspr
(contactin-associated protein) interacting with the glial protein
NF155 to form the junction (Figure 1; reviewed in Poliak and
Peles
11 and Pedraza et al.
12). The paranode appears to have
three primary roles in maintaining a stable saltatory conduction:
(1) spatial separation of Na
þ and K
þ channels, (2) sealing the
myelin sheath in a way that allows only selected nutrients to
diffuse into the internodal periaxonal space (space between the
myelin and axon) and (3) stabilization of the entire structure
in the face of mechanical stressors.
13 Recent reports have
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communication between the myelin and the axon (see below).
Techniques to identify oligodendrocyte-speciﬁc
alterations. Human postmortem studies frequently use
stains for Nissl bodies and nuclei to distinguish between
neuronal and glial cell populations, and close morphological
examination has been used to distinguish between glial
subtypes.
14 However, this technique limits the distinction
between different types of glial cells to morphological
markers (e.g. oligodendrocytes are characterized by
compact and uniformly darker nuclei). Fewer studies have
examined differences in glial cell subpopulations using
immunocytochemistry. Mature oligodendrocytes are
derived from oligodendrocyte precursor cells (OPC), which
develop in speciﬁc ventricular zones, migrate to their
ﬁnal site in the brain, and then differentiate. During this
time, a variety of proteins are expressed marking the
developmental stages of the cell, which could be utilized for
immunohistochemical identiﬁcation of both oligodendrocyte
precursor cells and mature oligodendrocytes in postmortem
subjects.
A relatively newly identiﬁed cell type expressing the
proteoglycan protein nerve/glial antigen-2 (NG2) shares a
common lineage with oligodendrocytes
15 and resembles
oligodendrocytes morphologically,
16 making it difﬁcult to
distinguish NG2þ cells from oligodendrocytes. NG2þ cells
express several markers common in oligodendrocyte pre-
cursor cells, including platelet-derived growth factor receptor,
alpha subunit and Olig1 and Olig2, however they do not
express markers for mature oligodendrocytes such as MBP,
PLP, CNP and O1.
17 In addition, NG2þ cells are able to ﬁre
action potentials,
18 express-voltage-gated ion channels,
19
and form unique contacts with neurons, oligodendrocytes and
astrocytes (reviewed in Verkhratsky and Butt
9), suggesting a
unique functional role that is only beginning to be explored.
Although not the focus of this review, imaging techniques
provide an alternative means of investigating biological
disturbances that relate to oligodendrocytes in live human
subjects, as myelin sheaths form the majority of brain white
matter. Magnetic resonance imaging (MRI) and diffusion
tensor imaging (DTI)can detect certain parameters that relate
towhitematterintegrity.Recently,signiﬁcantimprovementsin
resolution and analysis of imaging data have been made,
20
which will allow more thorough investigations of large-scale
oligodendrocyte-related alterations in live subjects.
Oligodendrocyte alterations in neuropsychiatric
disorders
There is evidence for oligodendrocyte alterations across most
psychiatric conditions, including but not limited to attention
deﬁcit and hyperactivity disorder, autism, bipolar disorder,
major depressive disorder (MDD), Alzheimer’s disease and
schizophrenia (reviewed in Fields
4). In schizophrenia, evi-
dence for oligodendrocyte disruption has been reported using
genetic, imaging and postmortem studies. Decreased oligo-
dendrocyte-related gene expression,
21–25 decreased oligo-
dendrocyte numbers and density,
26–28 and aberrant myelin
morphology
29 have been reported in various brain regions in
postmortem tissue from subjects with schizophrenia com-
pared to normal controls, including dorsolateral prefrontal
cortex, anterior cingulate cortex, superior temporal gyrus, and
hippocampus. Imaging studies using diffusion tensor imaging
indicate decreased white matter integrity in similar regions
thatmayexistpriortodiseaseonset(reviewedinTakahashiet
al.
30). Functional investigations of oligodendrocyte genes
altered in schizophrenia point toward disruptions in cell cycle
activity and axoglial interactions, particularly at the node,
thereby hinting at pathophysiological mechanisms.
31,32 Although
evidence in bipolar disorder is more limited, reports indicate
similar decreases in oligodendrocyte density,
26 oligodendro-
cyte-related genes primarily in the frontal cortex,
25,33,34 and
white matter abnormalities
35 (reviewed in McIntosh et al.
36
and Mahon et al.
37). Together, the current evidence in bipolar
disorder and schizophrenia has led to the support of a model
of disconnectivity via white matter tracts between the frontal
cortex and emotion regulation regions.
37,38 Thus, although
some regional speciﬁcity in white matter disruptions may
differentiate these disorders, it cannot be overlooked that
disruption of mood regulation is a common feature in these
disorders. In accord, patients with neurological disorders
affecting white matter (e.g. multiple sclerosis) often display a
high degree of comorbidity with psychiatric symptoms,
including depression,
39,40 and display similar patterns of
dysregulation in transcriptome proﬁles,
41 supporting the
hypothesis of a connection between disrupted oligodendro-
cyte function and mood dysregulation.
Primary evidence for oligodendrocyte alterations in
MDD. Primary evidence for glial alterations has been
reported for most of the major glial subtypes in MDD
(reviewed in Rajkowska and Miguel-Hidalgo,
2 Hercher
et al.
42 and Tham et al.
43). However, these changes are
often described under a broad nonspeciﬁc ‘glial umbrella’,
which we brieﬂy summarize here, before focusing on
oligodendrocyte-related changes in MDD. Postmortem
studies of brain regions implicated in MDD report volumetric
changes,
44 which may potentially reﬂect glial alterations. For
instance, studies in corticolimbic regions of MDD subjects
have described reductions in glial density or glia/neuron ratio
in the subgenual prefrontal cortex,
45 dorsolateral prefrontal
cortex,
46,47 orbitofrontal cortex,
46 anterior cingulate cortex
48
and amygdala.
49,50 In addition to reduced cell density,
increases in glial cell size were reported in the dorsolateral
prefrontal
46 and anterior cingulate cortices
51 of MDD subjects.
In contrast, a recent meta-analysis reported an increase in
S100B, a glial marker that is expressed primarily in astrocytes,
in MDD subjects compared with controls,
52 suggesting that
MDD may be associated with increases in glial cells. In
addition, several recent studies using morphometric analyses
have reported no changes in overall glial cells in the
orbitofrontal cortex and dorsolateral prefrontal cortex of late-
life MDD subjects,
53,54 all together leaving a muddled
consensus on total glial alterations in MDD.
Investigationswithglialspeciﬁcmarkershavenowbegunto
provide insight into glial subtype-speciﬁc disruptions in MDD
subjects. Decreases in several astrocytic markers (GFAP,
EAAT1, EAAT2) have been described in postmortem
human MDD subjects
55–57 and a recent report described the
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cingulate cortex of depressed subjects as evidence for a state
of chronic inﬂammation in white matter.
58 Rodent studies
have conﬁrmed and augmented these ﬁndings,
59–61 together
suggesting a model of astrocyte-mediated dysfunction/deple-
tion of prefrontal cortex glutamatergic cycling and home-
ostasis in MDD (reviewed in Valentine and Sanacora
62).
Increases in microglial density (using HLA-DR, a known
microglial marker for neurodegeneration and neuroinﬂamma-
tion) have been reported in a variety of brain regions in
psychiatric subjects who committed suicide, but normal
microglial densities have been reported in nonsuicide MDD
subjects.
63 In contrast, decreased proliferation of microglial
cells were reported in an animal model of MDD
64 leaving an
undeﬁnedpictureofmicroglial alterationsnot onlyinMDD, but
also in other neuropsychiatric disorders.
65
Recently, research has begun to focus on oligodendrocyte
and white matter abnormalities in human MDD subjects,
including postmortem tissue and live subjects, using imaging
approaches (reviewed in Tham et al.
43). Tissue level analysis
using the Kluver–Barrera staining method revealed that
staining intensity of deep white matter in the dorsolateral
prefrontal cortex was signiﬁcantly less intense in MDD
subjects compared with controls.
35 On a cellular level,
staining of Nissl bodies using morphological cell-type deter-
mination revealed that previously reported decreases in glial
cell number in amygdala and prefrontal cortex of MDD
subjects could be attributed to reduced oligodendrocyte
numbers.
26,50 A more recent study found a decreased density
of oligodendrocytes in the frontopolar cortex of human MDD
subjects using a novel approach of ﬂow cytometry on
ﬂuorescently labeled suspended nuclei.
66 However, to our
knowledge, no studies have examined oligodendrocyte
changes in MDD subjects using immunohistochemical tech-
niques for oligodendrocyte-speciﬁc markers.
Patterns of downregulation of oligodendrocyte-related gene
transcripts have been reported in human postmortem subjects
with MDD compared with control subjects in regions including
theamygdala,
67thenearbytemporalcortex,
22thedorsolateral
prefrontal cortex
68 and prefrontal cortex (BA 9) of MDD
subjects.
69 No signiﬁcant changes in a set of oligodendrocyte
genes selected a priori were observed in several subcortical
brain regions of MDD subjects, including putamen, internal
capsule and two thalamic nuclei,
70 suggesting selective
corticolimbic-speciﬁc and potentially other region-speciﬁc
oligodendrocyte disruptions in MDD. Other a priori studies of
myelin-associated genes revealed reductions in neurite out-
growth inhibitor isoform B mRNA in the frontal cortex of MDD
subjects,
71 reductionsin Quaking protein (an oligodendrocyte-
associated RNA-binding protein) in the cortex, hippocampus
and amygdala of MDD subjects
72 and downregulation of MBP
in the anterior frontal cortex of MDD subjects.
73
Areas of local demyelination appear on magnetic reso-
nanceimagingscansaswhitematterhyperintensities(WMH).
WMHsareassociatedwithnormalaging,butarethoughttobe
particularly prevalent in MDD subjects (reviewed in O’Brien
etal.
74).Studiesusinginvitromagneticresonanceimagingon
postmortem elderly human MDD subjects revealed that these
WMH may be due to vascular problems leading to cerebral
ischemia and eventual white matter lesions, in support of a
‘vasculardepression’hypothesis.
75Thereisalsoanextensive
literature of magnetic resonance imaging studies in live MDD
subjects, which have revealed abnormalities in white matter
(reviewed in Tham et al.
43). Brieﬂy, patients with late onset
depression (after age 45) have more frequent and intense
WMHs compared with early onset subjects, suggesting that
neuropathological changes in white matter may underlie late
onset depression, but not early onset depression.
76 WMHs
are also associated with cognitive impairments in late-life
depression,
77 and elderly MDD subjects with more pro-
nounced WMH have more severe longitudinal courses of
depression,
78 suggesting that WMHs could serve as markers
for clinical MDD diagnoses. Diffusion tensor imaging studies
have also revealed white matter abnormalities, particularly in
elderly subjects with late-life MDD (reviewed in Tham et al.
43
and Sexton et al.
79). White matter fractional anisotropy, a
measure of tract alignment and integrity, is consistently
reduced in frontal and temporal regions in MDD subjects,
80,81
is higher in antidepressant-resistant subjects,
82 and is
increased following electroconvulsive therapy (ECT).
83 More
recent diffusion tensor imaging studies in young MDD
subjects have also revealed altered white matter integrity.
84
Oligodendrocyte changes in animal models of
MDD. Evidence implicating decreased oligodendrocyte
components in MDD is paralleled by several studies in
rodent models. Rodents exposed to chronic stress show a
reduction in the proliferation of oligodendrocytes and NG2þ
cells in the frontal cortex, a pattern that is reversible with
antidepressant treatment.
85,86 Similarly, chronic corticosterone
stress hormone exposure in rodents resulted in decreased
cortical and amygdala oligodendrocyte
86 and NG2þ cell
proliferation,
64,87 together suggesting that oligodendrocytes
may be particularly susceptible to stress-related and
corticosterone-induced toxicity. Following electroconvulsive
seizures, a rat model for ECT in humans, nonstressed rats
showed increased proliferation of NG2þ cells in amygdala
and hippocampus
64,88,89 and increased proliferation of mature
oligodendrocyte cells in the frontal cortex.
90 In addition, similar
to human studies, oligodendrocyte transcripts were selectively
downregulated in the amygdala of mice exposed to unpre-
dictable chronic mild stress and these changes were reversed
by two types of antidepressant treatments.
91 Interestingly,
nonstressed rats or mice treated chronically with the anti-
depressant ﬂuoxetine displayed no changes in oligodendrocyte
proliferation in prelimbic cortex
92 or in oligodendrocyte-
related gene expression in cingulate cortex and amygdala,
91
suggesting that oligodendrocyte changes are speciﬁc to
chronic stress-induced pathology and may not be involved in
the mechanism of pharmacological antidepressant treatment.
Oligodendrocytes and neurons: a disease-prone
bidirectional balance?
New reports suggest that proper neuronal function depends
on a bidirectional balance between myelin and axons. This
may be a critical element that is disrupted in neuropsychiatric
disorders.
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alterations in neuropsychiatric disorders. Although it is
clear that oligodendrocyte deﬁcits are frequently observed in
neuropsychiatric disorders, the actual mechanisms that
induce oligodendrocyte alterations in the human brain remain
unknown; however, several models have been proposed: (1)
disturbances in chromatin regulation are implicated in MDD
93
and are suggested to lead to disruption of oligodendrocyte
differentiation and/or excitotoxicity;
94 (2) oligodendrocytes
express AMPA and kainate type glutamate receptors, and
are thought to be sensitive to excitotoxic damage from exces-
sive glutamate-mediated activation;
95 (3) the hypothalamic–
pituitary–adrenal axis is disrupted in MDD
96 and glucocorticoids
target oligodendrocytes
97 leading to decreased prolife-
ration,
86,87 suggesting that glucocorticoid-mechanisms are
involved in oligodendrocyte-related pathology; and (4) ﬁnally,
disruptions in dopaminergic transmission in MDD
98 could
also interfere with oligodendrocyte maturation via the
expression of D2 and D3 receptors on oligodendrocytes.
99
Notably, most current models converge on oligodendrocytes
being vulnerable to stress-related insults, suggesting that
these changes may be more frequent in MDD, owing to the
prevalent role of stress in precipitating MDD. This notion
provides support for the hypothesis that oligodendrocyte-
related changes are not speciﬁc to a particular psychiatric
disorder, and in fact may correspond to a cellular endo-
phenotype that is frequently observed across stress-related
and mental disorders. Hence, characterizing the etiological
causes and functional consequences of oligodendrocyte
dysregulations may have implications for major mental
illnesses at large.
Oligodendrocyte alterations elicit functional conse-
quences in neurons. The functional and mechanistic
consequences of disrupted oligodendrocyte structure are
poorly characterized, and it is not known whether they could
elicit downstream consequences related to mood disorders.
Although all glial cell types are important mediators of
neuronal function, increasing evidence is pointing toward
oligodendrocytes as a crucial component in the maintenance
of axonal integrity.
5,100 One of the primary functions of
oligodendrocytes is to promote axonal conduction and to
actively regulate neuronal properties.
11 However, oligoden-
drocytes also monitor neural activity through a variety of
receptors including glutamatergic (AMPA, NMDA, and
kainate) and GABAergic (GABAA) receptors, which both
depolarize the cell, the latter is caused due to high
intracellular levels of Cl
  at rest (reviewed in Verkhratsky
and Butt
9). For instance, activation of glutamate receptors on
oligodendrocytes leads to depolarization of the cell, an action
that rapidly modulates axonal conduction velocity.
101,102 In
turn, action potentials in the ensheathed axons can stimulate
depolarization of oligodendrocytes.
101
Direct manipulation of myelin structure also leads to
alterations in neuronal properties. Cuprizone, a copper
chelator, which causes global demyelination in rodents when
administered orally, alters the distribution of ion channels at
the critical nodal region,
103 and produces changes in axonal
conduction velocity.
104 Mice deﬁcient in PLP, an oligoden-
drocyte-speciﬁc structural protein involved in lamellae fusion,
show disruption of fast axonal transport,
105 while PLP-
overexpressing mice have altered neuronal conduction
velocity and refractory periods.
106 Furthermore, mice lacking
structural myelin components, including PLP, CNP, and
myelin-associated glycoprotein, all have relatively normal
myelinassembly,butdevelopprogressiveneurodegeneration
(reviewed in Nave and Trapp
107), pointing toward myelin as a
regulator of axon trophic support. Nave and colleagues
have proposed that trophic support from oligodendrocytes
(for example, metabolites or neurotrophic factors) is required
for mitochondrial energy metabolism in axons, as the myelin
sheath itself restricts axonal access to extracellular metabolic
substrates.
5,108 Thus, oligodendrocyte disruptions may cause
reduced metabolic couplingbetween the myelin and the axon,
leading to structural and functional impairments.
Alterations in oligodendrocytes elicit mood-related
symptoms in rodents
Whether the previously described decreased oligodendrocyte
components in neuropsychiatric illnesses and rodent models
of the disorder are causal to the behavioral phenotype is unknown.
Toaddressthisquestion,severalstudieshaveusedchemically
induced lesions or genetic manipulations to investigate the
behavioral consequences of oligodendrocyte disruption.
Chemical lesions. The cuprizone model of demyelination in
mice has mainly been utilized in schizophrenia-related
behavioral studies.
109 Mice treated with cuprizone show
reduced anxiety-like behavior in the open ﬁeld and elevated
plus maze tests, decreased social interaction, decreased
pre-pulse inhibition, less spontaneous alternation in the
Y-maze and decreased motor coordination.
110–112
Cuprizone treatment also causes deﬁcits in frontal cortex-
mediated cognitive tasks in rats along with decreased
oligodendrocyte transcripts speciﬁcally in prefrontal regions
(not hippocampus or striatum).
113 However, the cuprizone
model induces widespread demyelination in the brain
and causes severe locomotor, social and cognitive
consequences that could confound behavioral tasks,
together making it difﬁcult to discern emotionality changes
speciﬁc to myelin disruption. Another demyelinating agent,
lysolecithin, induced anxiety-like behaviors in the elevated
plus maze and open ﬁeld tests along with hyperactivity when
injected directly into the hippocampus.
114 Furthermore, early
weaning induces anxiety-like behaviors in adulthood that are
associated with alterations in whole-brain MBP expression
115
and early myelin formation, speciﬁcally in the amygdala of
male, but not female mice.
116 Together, this evidence
indicates that demyelination can inﬂuence anxiety- and
depression-related behaviors (i.e. emotionality) in rodents.
Genetic approaches. Similar to rodents with chemically
induced lesions, mice mutant for certain oligodendrocyte-
speciﬁc genes (e.g. MBP, MOBP, CASPR, CNP1) also
display altered locomotor activity and motor coordination
deﬁcits.
5,107 However, emotionality behaviors have rarely
been examined in these mutants. Our laboratory recently
tested the potential mechanistic link between altered
oligodendrocyte function and emotionality in mice by
Oligodendrocytes in mood regulation
N Edgar and E Sibille
4
Translational Psychiatrythoroughly examining behavioral characteristics in mice
lacking CNP1 (CNP1
KO), an oligodendrocyte-speciﬁc gene
that is localized to the paranode and that has previously been
implicated in MDD
67 and schizophrenia.
117–119 CNP1
KO mice
display motor coordination deﬁcits beginning at 7–9 months
of age.
120,121 Therefore, we examined emotionality-related
behaviors before the onset of these deﬁcits in order to avoid
those potential confounding effects. We found that CNP1
KO
mice display a progressive age-related (3, 6 and 9 months)
decrease in emotionality (anxiety- and depressive-like
behaviors) under nonstressed conditions.
120 Interestingly,
young (3- and 6-months old) CNP1
KO mice were resistant to
developing high emotionality states following exposure to
either unpredictable chronic mild stress or chronic
corticosterone, two well-established paradigms to induce
high emotionality, with construct, face and predictive
validities as rodent models of depression.
120 In addition,
CNP1
KO mice show low fear expression during the extinction
phase of a fear conditioning paradigm,
120 a behavior that is
indicative of a disruption in emotion-related circuits. In
humans, stress resilience is associated with the ability to
adapt to chronic stress
122 and the ability to perceive stressful
events in a less threatening way.
123 In addition, resilient
individuals are thought to have optimal functioning of fear
extinction mechanisms
122 and ‘an ability to quickly attenuate
learned fear through a powerful extinction process’.
124
Hence, the pattern of behavioral and amygdala-mediated
dysfunctions observed in CNP1
KO mice suggests a pheno-
type characteristic of stress resilience. It is currently not
known whether this apparent contradiction—low CNP in
human MDD and resiliency in CNP1
KO mice — results from
maladaptive compensatory changes, or from the selective
disruption in mice of a single component extracted
from a broader dysregulated gene pattern in human
MDD (see Edgar et al.
120 for discussion). Similar to
CNP1
KO mice, mice overexpressing PLP display reduced
anxiety-like behaviors in the elevated plus maze, along with
signiﬁcantly reduced axonal conduction velocity.
125
In combination with reports using chemical lesions of
myelin, these data suggest that oligodendrocytes have a role
in regulating stress responsiveness and that changes in
oligodendrocyte structure and function can impact circuits
mediating emotionality in mice; although the precise mechan-
isms underlying these effects are unclear. However, mouse
behaviorsare oftendifﬁcult to interpret and categorize, andan
alternative interpretation of the CNP1
KO phenotype could
be a manic-like phenotype (i.e. hyperactivity and low anxiety-
likebehaviors),moreakintoaspectsofbipolardisorder.Thus,
studies using genetic manipulation or demyelinating agents in
region- and time-speciﬁc manners, combined with functional
(i.e., electrophysiology) and broader phenotypic character-
izations are needed to further reﬁne the role and contribution
of oligodendrocytes in the function of neural circuits under-
lying mood and associated disorders.
The paranode as a proposed site of dysregulation
in neuropsychiatric disorders
The paranode region of oligodendrocytes is a critical site
of interaction between myelin and axons (reviewed in
Rosenbluth
13), and recent studies investigating the putative
role of oligodendrocyte alterations in psychiatric disorders,
including MDD and schizophrenia, suggest that the nodal and
paranodal regions of oligodendrocytes may represent
important sites of dysregulation (Figure 1).
4,100,126
Ablation of paranodal proteins, such as CNP1 and CASPR,
cause structural disorganization at the paranode,
127,128 which
could lead to electrophysiological changes in the axon.
Indeed, in mice lacking CASPR, the paranode region fails to
form, and these mice exhibit decreased nerve conduction
velocity,
129 supporting a role for the paranode region in
maintaining proper axonal signal transmission. In addition,
mice overexpressing PLP exhibit abnormal paranodal struc-
ture, including everted paranodal loops, lack of proper cell
junctions and abnormal CASPR clustering in forebrain
regions, in parallel with behavioral and electrophysiological
abnormalities.
125 Yamazaki et al.
130 speculate that structural
changes such as swelling, particularly at the paranode,
could drastically alter neuronal insulation properties
resulting in changes to leak currents that could impact the
speed of depolarization. Conversely, repetitive action poten-
tial propagation in neurons leads to paranodal swelling,
131
perhaps due to osmotic water ﬂux,
102 again highlighting
the balance between axons and their myelin sheath.
Structural changes to the paranode (e.g. CASPR ablation)
also result in accumulation of mitochondria at the node
and paranode (in peripheral samples),
132 supporting Nave’s
hypothesis of altered metabolic coupling between the myelin
and axon.
5
As described above, the lack of CNP1, a paranodal-
associated gene product, can impact the function of the
amygdala, a critical region within a broader corticolimbic
circuitry ofaffect-regulationandassociatedbehaviorsinmice.
This evidence supports an active contribution of altered
oligodendrocyte structure and function to mood-related
behavioral phenotypes and symptom dimensions observed
in human MDD, and possibly schizophrenia. However, the
CNP1
KO rodent studies are somewhat surprising, in that they
point to a potential decrease in emotionality, which may also
relate to behavioral aspects of bipolar disease. Together, the
data suggest a complex balance between neuron and
oligodendrocyte functions in modulating the function of neural
networks underlying affect regulation. The accumulated
evidence points toward the paranode, as a signiﬁcant
structural and functional interface between axons and the
myelin sheath, which may be selectively vulnerable to
glucocorticoids, stress-related insults or more simply, to
increased and sustained recruitment, as occurring in emo-
tion-processing areas such as the amygdala. These events
would in turn lead to altered homeostasis (e.g. osmotic and
metabolic stress) at this critical region of axoglial commu-
nication. In a simpliﬁed model (Figure 1), impaired paranode
integrity may lead to local cellular dysfunction and improper
axonal conduction, resulting in loss of integrity of information
transfer; which, in the context of amygdala dysfunction in
MDD, we speculate may underlie the deregulated affect-
related phenotype.
In summary, oligodendrocytes provide critical support to
neuronal function and display patterns of dysregulation in
MDD, schizophrenia and bipolar disorder, which are distinct
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the human postmortem brain demonstrates shared features
across major mental illnesses, and current models of
oligodendrocyte pathophysiological vulnerability converge
on stress-related insults. Together, this suggests that
oligodendrocyte-related changes are not speciﬁc to any
psychiatric disorder, and may instead represent a cellular
endophenotype that is downstream from etiological and
pathophysiological events that are frequently recruited in
major mental illnesses. The critical role of stress in precipitat-
ing depressive episodes may explain the more prevalent
corticolimbic patterns of oligodendrocyte changes in MDD.
On the other hand, emerging data from rodent studies
suggest that oligodendrocyte dysfunction, including both
structural and functional changes of the axoglial paranode
interface, may exert modulatory roles on neural circuitry
underlying mood regulation. It is conceivable that these
disruptions may manifest as different phenotypes (or ill-
nesses) depending upon the developmental timing, affected
region and extent of pathophysiology. Hence, investigating
the etiological factors that lead to oligodendrocyte
dysfunction, and their bidirectional links with neuronal
dysfunction, while characterizing the functional conse-
quences of such disruptions, may have implications for
mechanisms and treatments of symptom dimensions across
major mental illnesses.
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